HIV shots tested in pregnancy: a step toward easier treatment for moms
NCT ID NCT07637942
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how long-acting injectable HIV drugs (cabotegravir and rilpivirine) work in the body during pregnancy and after childbirth. About 40 pregnant women with HIV will receive the shots every 4 weeks. The goal is to measure drug levels and see if they stay effective, helping to keep the mother healthy and reduce the risk of passing HIV to the baby.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Long-acting injectable cabotegravir and rilpivirine
What this could lead to
If successful, this could show that long-acting HIV shots work well during pregnancy, offering a convenient option for pregnant women with HIV.
What could go wrong
This is a small, early-phase study (40 participants) focused on drug levels, not on proving the drugs prevent HIV transmission. Results may not apply to all women, and there are unknown risks during pregnancy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site 4001, Lurie Children's Hospital of Chicago CRS
Chicago, Illinois, 60614, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 4601, University of California, UC San Diego CRS
La Jolla, California, 92093, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 5013, Jacobi Medical Center Bronx
The Bronx, New York, 10461, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 5030, Emory University School of Medicine
Atlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 5048, University of Southern California
Los Angeles, California, 90033, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 5052, University of Colorado
Aurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 5092, Johns Hopkins University
Baltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 5128, Baylor College of Medicine/Texas Children's Hospital
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 6201, University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 6501, St Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••